Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.54 |
| ▸ | KRAS | P01116 | 2/20 | 0.52 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28810229 | 0.94 | USP30 (0.61) | USP30KRASFPR3FPR2PARP1 | |
| SCHEMBL29753933 | 0.89 | USP30 (0.44) | USP30KRASFPR3FPR2POLB | |
| SCHEMBL31123851 | 0.89 | USP30 (0.44) | USP30KRASFPR3FPR2POLB | |
| SCHEMBL28923421 | 0.81 | USP30 (0.56) | USP30FPR3FPR2POLBEPHX1 | |
| SCHEMBL25192922 | 0.81 | USP30 (0.56) | USP30FPR3FPR2POLBEPHX1 | |
| SCHEMBL23533875 | 0.80 | USP30 (0.55) | USP30KRASFPR3FPR2POLB | |
| SCHEMBL29753978 | 0.80 | USP30 (0.53) | USP30KRASFPR3FPR2POLB | |
| SCHEMBL23533945 | 0.80 | USP30 (0.53) | USP30KRASFPR3FPR2POLB | |
| SCHEMBL28810999 | 0.78 | NPC1 (0.48) | USP30KRASPOLBKMT2AALDH1A1 | |
| SCHEMBL28579659 | 0.78 | USP30 (0.52) | USP30FPR3FPR2POLBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-07-31 | — | — | US | disclosed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4079732-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867718-A | Novel indazole derivative and use thereof | 韩国化学研究院 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021125802-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | USP30 2567/4885KRAS 3978/4885FPR3 223/4885 |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | USP30 2567/4885KRAS 3978/4885FPR3 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.